Target intelligence / Profile preview

Haemophilus influenzae type a capsular polysaccharide (Hia CPS)

Target
Hia CPS
Molecular classification
Bacterial polysaccharide, Bacterial antigen, Carbohydrate
01

Overview

The Haemophilus influenzae type a capsular polysaccharide (Hia CPS) is a critical virulence factor for the Hia bacterium, consisting of a repeating unit of [→4)-β-D-glucopyranosyl-(1→3)-D-ribitol-5-phosphate-(1→]. This polysaccharide capsule acts as a protective barrier that allows the pathogen to evade the host's innate immune system by resisting phagocytosis and complement-mediated lysis. While Haemophilus influenzae type b (Hib) was historically the primary cause of invasive disease, the success of Hib conjugate vaccines has led to the emergence of Hia as a significant cause of severe infections, including meningitis and pneumonia, particularly in indigenous populations. As a therapeutic target, the Hia CPS is utilized in the development of conjugate vaccines where the polysaccharide is chemically linked to a carrier protein to induce a T-cell dependent immune response. These vaccines aim to generate high-affinity IgG antibodies and immunological memory to provide long-term protection against invasive Hia disease.

Other names
Hia capsular polysaccharideSerotype a capsular polysaccharideHaemophilus influenzae serotype a polysaccharideHia antigen
02

Mechanism of action

Induction of polysaccharide-specific IgG antibodies that facilitate opsonophagocytosis and complement-mediated killing of the bacteria.

03

Biological functions

Virulence factorEvasion of host immune systemProtection against phagocytosisBacterial structural integrity
04

Disease associations

InfectionMeningitisPneumoniaBacteremiaEpiglottitisSeptic arthritis
05

Safety considerations

Hypersensitivity reactionsInjection site reactionsPotential for serotype replacementInterference with other conjugate vaccines
06

Interacting drugs

Hia-CRM197 conjugate vaccine

1 more in the full profile.

07

Biomarkers

Anti-Hia IgG antibody titerSerum bactericidal activity (SBA)Opsonophagocytic assay (OPA) activity

Beyond the preview

Go deeper on Haemophilus influenzae type a capsular polysaccharide (Hia CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haemophilus influenzae type a capsular polysaccharide (Hia CPS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call